Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.

Georg WolffYingfeng LinCihan AkbulutMaximilian BrockmeyerClaudio ParcoAlexander HossAlexander SokolowskiRalf WestenfeldMalte KelmMichael RodenSabrina SchlesingerOliver Kuss

Published in: ESC heart failure (2022)

We found only modest treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors for CM and HHF in primary type 2 diabetes mellitus populations. In primary heart failure populations, SGLT2 inhibitor benefits were substantial and comparable in efficacy to established heart failure medication.

Keyphrases

heart failure
left ventricular
healthcare
acute heart failure
atrial fibrillation
cardiac resynchronization therapy
genetic diversity
type diabetes
emergency department
glycemic control
metabolic syndrome
adverse drug
smoking cessation